{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-265706","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.065554+00:00","generated_at":"2026-05-17T00:12:32.003689+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"EyePoint Q3 net revenue $1.0M, net loss $59.7M; DURAVYU Phase 3 fully enrolled; $172.5M financing","bullets":["Q3 2025 total net revenue fell to $1.0M from $10.5M YoY; net loss widened to $59.7M ($0.85/share) vs $29.4M ($0.54/share).","Cash, equivalents & securities $204M at Sep 30; Oct public offering added $162M net, extending runway into Q4 2027.","Phase 3 LUGANO/LUCIA for wet AMD fully enrolled (>900 patients); topline data expected mid-2026, first-to-market target.","Initiated pivotal Phase 3 DME program (COMO, CAPRI) with FDA non-inferiority pathway; first dosing in Q1 2026.","Preclinical data shows DURAVYU inhibits IL-6 inflammation plus VEGF, supporting multi-target mechanism in retina."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-265706","json":"https://secwatch.observer/filing/0001193125-25-265706.json","markdown":"https://secwatch.observer/filing/0001193125-25-265706.md","text":"https://secwatch.observer/filing/0001193125-25-265706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312525265706/0001193125-25-265706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312525265706/eypt-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:12:32.003689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}